Abstract: Indolent B-cell lymphomas constitute a slow growing cancer of the lymphatic system. These lymphomas mainly include fol-licular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstom macroglobulinemia, marginal zone lym -phoma, and low malignant mantle cell lymphoma. These lymphomas are sensitive to chemotherapy and/or immunochemotherapy, but they cannot be cured. Furthermore, patient age at diagnosis, patient age at time of first onset or subsequent relapses, and compli-cations often influence the chemotherapy curative effect. At present, recent progress has been achieved in our understanding of dys -regulated pathways and immunologic anti- tumor responses in indolent lymphoma. In particular, the breakthrough of non- cytotoxic drugs renders "chemo-free" treatment a near-future reality. In this review, we highlight these promising approaches, such as the com-bination of anti-CD 20antibodies with immunomodulatory drugs, mAbs directed against other surface antigens, and programmed cell death 1 (PD- 1) receptor inhibitor or B- cell receptor signaling pathway inhibitors. Future phase III studies will evaluate the efficacy of these drugs in the context of non-chemotherapy and further clarify treatment status.